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Abstract
Natural killer (NK) cells are stimulated by ligands on virus-infected cells. We have recently demonstrated that NK cells
respond to human immunodeficiency virus type-1 (HIV-1)-infected autologous T-cells, in part, through the recognition of
ligands for the NK cell activating receptor NKG2D on the surface of the infected cells. Uninfected primary CD4pos T-cell blasts
express little, if any, NKG2D ligands. In the present study we determined the mechanism through which ligands for NKG2D
are induced on HIV-1-infected cells. Our studies reveal that expression of vpr is necessary and sufficient to elicit the
expression of NKG2D ligands in the context of HIV-1 infection. Vpr specifically induces surface expression of the unique-long
16 binding proteins (ULBP)-1 and ULBP-2, but not ULBP-3, MHC class I-related chain molecules (MIC)-A or MIC-B. In these
studies we also demonstrated that Vpr increases the level of ULBP-1 and ULBP-2 mRNA in primary CD4pos T-cell blasts. The
presence of ULBP-1 and ULBP-2 on HIV-1 infected cells is dependent on the ability of Vpr to associate with a protein
complex know as Cullin 4a (Cul4a)/damaged DNA binding protein 1 (DDB1) and Cul4a-associated factor-1(DCAF-1) E3
ubiquitin ligase (Cul4aDCAF-1). ULBP-1 and -2 expression by Vpr is also dependent on activation of the DNA damage sensor,
ataxia telangiectasia and rad-3-related kinase (ATR). When T-cell blasts are infected with a vpr-deficient HIV-1, NK cells are
impaired in killing the infected cells. Thus, HIV-1 Vpr actively triggers the expression of the ligands to the NK cell activation
receptor.
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Introduction
NK cells are involved in the immune response against tumor
cells and virus-infected cells without the requirement for previous
exposure to their targets or their products. The importance of NK
cells in restraining viral infection was first shown in studies using
murine models in which NK cells were depleted [1,2,3]. In these
studies, NK cell depletion led to enhanced viral replication and
cytopathology. In humans, NK cells control the severity of viral
infections such as those by herpes simplex virus [4,5], cytomeg-
alovirus [6] and hepatitis B virus [7]. Lack of NK cells in humans
or defects in NK cell function are associated with fatal
disseminated herpes virus infection [8,9,10,11,12,13].
One of the major roles of NK cells in controlling viruses is the
destruction of the infected cells. Direct target cell killing by NK
cells is mediated by the regulated release of granules containing
perforin and granzymes [14,15]. Perforin forms pores in the
plasma membrane allowing ions and small particles into and out of
the cell [16]. The granzymes most likely enter the target cell
through perforin-formed channels [17] or endocytosis [16] and
induce apoptosis of the infected cells. NK cells may also kill
through engagement of death receptors (e.g., Fas) by ligands
expressed on the NK cell surface (e.g., CD178) whose surface
expression is increased upon degranulation [18]. In vivo, cytotoxic
function is primarily mediated by the subset of NK cells that are
CD56dim/CD16pos, the dominant subset in the peripheral blood of
healthy individuals [19]. CD56bright/CD16neg cells constitute a
minor NK population in the blood but are the major NK cell
subset in secondary lymphoid tissues. CD56bright NK cells express
less perforin than CD56dim NK cells but higher concentrations of
cytokines and as such are important in regulating immune
responses.
NK cell release of cytotoxic contents is regulated by a large
array of signals provided by a variety of membrane-bound,
activating receptors expressed on NK cells that interact with their
corresponding ligands on target cells (see [20] for a current list of
all known activating receptors and their ligands). Almost all NK
cell activating receptors interact with adaptor proteins containing
activation domains [20]. Activation receptors can be divided into
those associated with intracellular tyrosine activation motifs
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(ITAM)-containing adaptor molecules and those associating with
adaptor molecules lacking ITAMs. ITAM-dependent receptors
include: CD16 (low affinity IgG receptor), and the natural
cytotoxicity receptors (NCRs; NKp30, NKp44 and NKp46)
[21]. The NKG2D receptor is an example of an ITAM-
independent activation receptor. NKG2D is found on almost all
peripheral blood NK cells and is a member of the NKG2 receptor
family. NKG2D does not associate with CD94, but forms homo-
dimers on the membrane of NK cells [22,23]. Although NKG2D
specifically recognizes its ligands on target cells and is important
for activation of NK cells, it does not induce signal transduction
within the cells. For this purpose, NKG2D associates, on the
membrane, with the DAP10 adaptor molecule. The DAP10
adaptor protein contains a YXXM motif instead of ITAM and
recruits phosphatidylinositol-3- kinase and Grb-2 upon phosphor-
ylation [20].
Our prior studies [24,25] and those of others [26] indicate that
HIV-1-infection of primary CD4pos T-cells leads to the surface
expression of NKG2D ligands. The ligands for human NKG2D are
theMIC-A and -B and ULBP 1–4 [27,28]. ULBPs but notMIC-A or
-B were found on the surface of HIV-infected cells in our prior
studies.We not only found thesemolecules on in vitro infected primary
CD4pos T-cell blasts but also on infected cells obtained from HIV-1-
infected patients after amplification of the virus-infected cells ex vivo
[25]. In addition, these studies, which used primary CD4pos T-cells
infected with HIV-1 as targets for autologous NK cells in cytotoxicity
assays, revealed that NK cells can respond to the HIV-1-infected cells
in an NKG2D-dependent manner [24,25].
A recent study by Gasser et al. demonstrated, that DNA damage
induced expression of a plethora of NKG2D ligands [29]. The up-
regulation of NKG2D ligands occurred after the activation of the
DNA damage recognition enzymes ataxia telangiectasia mutated
(ATM) and ATR [29]. The HIV-1 Vpr protein is a potent
activator of ATR, and induces infected cells to arrest in the G2
phase of the cell cycle, [30,31] and increases viral transcription
from the HIV-1 long-terminal repeat [32,33,34]. Our previous
studies have demonstrated that the ability of Vpr to induce cell
cycle arrest in G2 is dependent on activation of ATR but not ATM
[30,35]. Therefore, we hypothesized that HIV-1 Vpr is responsible
for inducing the expression of NKG2D ligands during infection
through activation of ATR. We further hypothesized that Vpr-
mediated up-regulation of NKG2D ligands would lead to NK cell
activation. If these hypotheses are correct, this would indicate that
the DNA damage signaling by Vpr has consequences that may
potentially be detrimental to the virus because they enhance
immune surveillance by NK cells.
Results
Vpr induces expression of the NKG2D ligands, ULBP-1
and ULBP-2
Initially, we determined the role of Vpr in the up-regulation of
NKG2D ligands on primary CD4pos T-cells. To eliminate possible
differences in replication kinetics due to the presence or absence of
Vpr [32,33], we used a defective HIV-1 construct, DHIV, that has
a deletion in the env gene. We then provided the VSV-G
glycoprotein in trans, to form pseudotyped virions [36,37]. In
humans, six different NKG2D ligands have been reported to date.
In order to be able to detect global changes in the expression of all
six NKG2D ligands, we utilized a recombinant soluble NKG2D
receptor that binds to all of them. We stained the cells with
viability dyes and evaluated only the viable infected population for
expression of NKG2D ligands (Figure S1).
We tested the binding of soluble NKG2D as a measure of ligand
expression in PBMC from five individuals, in the presence or
absence of in vitro DHIV infection. As seen in Figure 1A, CD4pos T-
cells infected with DHIV wild type (WT) expressed NKG2D ligands
[MFI= 687 for infected cells (HIV-1 p24 Agpos/CD4neg) compared
with MFI=159 for uninfected control]. Experiments were per-
formed in parallel for a total of 5 donors and the statistical difference
in MFI between the infected and uninfected groups in five
individuals was p,0.01 based on the Student’s t-test. Uninfected
cells did not detectably express NKG2D ligands (MFI=152 for
uninfected cells compared with MFI=159 for secondary Ab
staining). Within the infected population, only the HIV-1 p24 Agpos
cells, but not the p24neg in the same culture, expressed NKG2D
ligands (see Figures 1 and S2). Therefore, we conclude that NKG2D
is not induced on uninfected, bystander cells. DHIV does not encode
the envelope glycoprotein; however NKG2D ligands are also
induced on envelope-expressing HIV-1NL4/3-infected cells
(Figure 1B). DHIV is derived from HIV-1NL4/3. Thus, DHIV-
infected cells express NKG2D ligands on their cell surface.
We then sought to determine whether Vpr was responsible for
the expression of NKG2D ligands. We generated DHIV
containing a truncation in Vpr. As controls, mutants of DHIV
unable to express Vif, Vpu or Nef were also generated. Figures 2
and S2 illustrate that the DHIV-DVpr infected cells failed to
induce NKG2D ligand expression (Figure 2B; MFI= 188 for HIV-
1 p24 Agpos/CD4neg infected cells and MFI= 216 for HIV-1 p24
Agneg/CD4pos infected cells). The MFI for DHIV-WT infected
cells was statistically different (p,0.01) compared to the MFI for
DHIV-DVpr infected cells. We compared expression of NKG2D
ligands on CD4pos T-cells infected with DHIV-DVif (Figure 2C;
MFI= 600 for HIV-1 p24 Agpos/CD4neg infected cells and
MFI= 260 for HIV-1 p24 Agneg/CD4pos infected cells), DHIV-
DVpu (Figure 2D; MFI= 777 for HIV-1 p24 Agpos/CD4neg
infected cells and MFI= 247 for HIV-1 p24 Agneg/CD4pos
infected cells), and DHIV-DNef (Figure 2E; MFI= 698 for HIV-
1 p24 Agpos/CD4neg infected cells and MFI= 303 for HIV-1 p24
Agneg/CD4pos infected cells). Therefore, expression of NKG2D
ligands induced by DVif, DVpu and DNef DHIV was comparable
that induced by WT DHIV (Figure 2A). Thus, we conclude that
Vpr is required for HIV-1-mediated up-regulation of NKG2D
ligands on the surface of infected cells.
To determine whether Vpr expression is sufficient to induce
NKG2D ligands, we resorted to a lentiviral vector that encodes HIV-1
Author Summary
Natural killer (NK) cells are part of the innate immune
response against virus infection and cancer. Recently we
demonstrated that ligands for the NK cell activation
receptor, NKG2D, trigger NK cell-mediated response to
infected cells. These ligands are expressed on HIV-1-
infected cells and not on uninfected cells. Despite the
observation that NKG2D ligands are expressed on infected
cells, it is unclear how HIV-1 induces their expression. In
the present study, we demonstrate that HIV induces the
ligands of the NKG2D receptor through the viral gene
product Vpr. Vpr triggers a DNA damage response in
infected cells, which in turn, increases virus production. We
also demonstrate that by blocking the activity of ATR, a
major component in the DNA damage response, we were
able to prevent NKG2D ligand expression. When Vpr was
removed from the virus genome, NK cells lost their ability
to lyse the HIV-infected cells. Thus, HIV-1 actively triggers
NK cells through the activity of its viral gene product, Vpr.
HIV-1 Vpr Induces Expression of NKG2D Ligands
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Vpr and GFP but no other viral gene (pPR-VIP). As a control, we used
a similar lentiviral vector encoding only GFP. We observed that Vpr
alone, but not the control lentiviral vector, was able to induce NKG2D
ligands on CD4pos T-cells (Figure 3). Therefore, Vpr is sufficient for
HIV-1 to induce NKG2D ligands on the infected cell surface.
The studies illustrated in Figures 1–3 utilized a soluble NKG2D
construct that is unable to distinguish between the various ligands.
Hence, we wished to determine which of the NKG2D ligands
were specifically induced by Vpr. For this purpose, we compared
the expression of ULBP-1, ULBP-2, ULBP-3, MIC-A and MIC-B
on DHIV-infected cells. In the studies shown in Figure 4, we
demonstrate that WT virus induced ULBP-1 (Figure 4A;
MFI= 483 for WT virus-infected cells compared with MFI= 167
for uninfected cells) and ULBP-2 (Figure 4C; MFI= 539 for WT
virus-infected cells compared with MFI= 131 for uninfected cells).
In contrast, little or no induction of ULBP-3 (Figure 4E;
MFI= 150 for WT virus-infected cells compared with MFI= 134
for uninfected cells), MIC-A (Figure 4G; MFI= 187 for WT virus-
infected cells compared with MFI= 106 for uninfected cells) or
MIC-B (Figure 4I; MFI= 99.8 for WT virus-infected cells
compared with MFI= 90.5 for uninfected cells) was detected.
DHIV-DVpr induced considerably lower levels of ULBP-1
(Figure 4B; MFI= 220 for DVpr virus-infected cells compared with
MFI= 485 for WT virus-infected cells) and ULBP-2 (Figure 4D;
MFI= 179 for DVpr virus-infected cells compared with MFI= 539
for WT virus-infected cells) than WT virus. Thus, HIV-1 primarily
induces the expression of ULBP-1 and ULBP-2 through Vpr.
Induction of ULBP-1 and ULBP-2 by Vpr occurs at the
level of gene expression
Next we asked whether induction of NKG2D ligands on infected
cells was accomplished through increased steady-state levels of
ULBP-1 and ULBP-2 mRNA. We infected CD4pos T-cells with
DHIV and select mutants, and then measured the mRNA levels of
ULBP-1, ULBP-2, ULBP-3, MIC-A andMIC-B relative to the level
of GADPH mRNA (Figure 5). We found that both ULBP-1 and
ULBP-2 mRNA levels were 15-fold higher in WT virus-infected
cells compared with ULBP-1 and ULBP-2 gene products in
uninfected cells. In comparison toWTDHIV-infected cells, DHIV-
DVif-infected cells showed little or no changes in ULBP-1 and
ULBP-2 mRNA levels. In addition, in DHIV-DVpr-infected cells,
the levels of ULBP-1 and -2 mRNA were 3 to 10-fold lower
compared with those in WT DHIV-infected cells (Figure 5).
Infection with WT DHIV only induced a 1.5-fold increase in the
expression ULBP-3, MIC-A and MIC-B. Thus, among the five
NKG2D ligands we evaluated, Vpr is responsible for up-regulating
the levels of ULBP-1 and ULBP-2 mRNA in HIV-1-infected cells.
Expression of NKG2D ligands requires Vpr’s ability to
interact with the Cullin 4aDCAF-1 E3 ubiquitin ligase and
to activate ATR
Vpr induces G2 arrest of infected cells through interaction with
a Cul4a-based ubiquitin ligase that also contains the adaptor,
DDB1, and the substrate receptor, DCAF1 (reviewed in [38]).
Figure 1. Infected primary CD4pos T-cells express NKG2D ligands. DHIV (A) and HIV-1NL4/3 (B) -infected primary T-cell blasts and uninfected
CD4pos T-cells were surface stained with fluorochrome-conjugated anti-CD4 Ab and a fusion protein of human NKG2D and the Fc portion of human
IgG1 along fluorochrome-conjugated goat anti-human IgG1. All cells were stained intracellularly for HIV-1 p24 antigen (Ag). Histograms were derived
following acquisition on a flow cytometer of either 104 viable cells [(for uninfected cells) blue line] or 104 viable CD4neg cells and HIV-1 p24 Agpos
infected cells (red line). As controls (green line), cells were stained with secondary Ab alone. This figure is representative of five separate experiments.
doi:10.1371/journal.ppat.1000613.g001
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Despite the fact that the degradation target for this ubiquitin ligase
is unknown, the consequences of the Vpr-E3 complex are well
documented. The main result is the activation of the ATR kinase
[39] that, in turn, leads to G2 arrest [35]. Therefore, we wished to
determine whether Vpr recruitment of the Cullin-4a-based E3
ubiquitin ligase complex is required for ULBP-1 and -2 expression.
We first tested whether domains in Vpr that are involved in
recruiting or activating the Cullin-4a-based E3 ubiquitin ligase
were required for induction of ULBP-1 and ULBP-2. The Vpr
Q65R and Vpr R80A mutations have been previously shown to
abate the ability of Vpr to induce cell cycle arrest [39,40]. Vpr
Q65R is unable to bind to DCAF1; the exact defect induced by
R80A mutation is unknown, and it has been proposed that R80A
abates the interaction between Vpr and the ubiquitination target
for the E3/Vpr complex [39,40]. For this purpose, we generated
DHIV mutants with the above substitutions in Vpr. As shown in
Figure 6, expression of NKG2D ligands was diminished by either
substitution, although Vpr(R80A) had a more dramatic effect than
Vpr(Q65R) (18 percent of wild-type Vpr and 48 percent of wild-
type Vpr, respectively). The cell cycle profiles were examined in
infected cells to visualize functional deficits in these mutants.
When Vpr R80A or Vpr Q65R, were expressed neither mutant
virus could induce G2 arrest as effectively as WT virus (Figure S3).
To more directly assess the requirement of the Cullin-4a-based E3
ubiquitin ligase in inducing NKG2D ligand expression, we resorted
to RNA interference-mediated depletion of DCAF1 (Figure 7).
Results shown in Figure S4 demonstrate that infection with HIV-1
and indicated mutant viruses had no effect on the levels of DCAF1
protein. We generated a lentivirus vector, based on FG12 [41],
expressing short hairpin RNAs (shRNAs) specific for DCAF1 [42].
Knockdown of DCAF1 expression completely abated the ability of
WT DHIV to up-regulate NKG2D ligand expression (Figure 7C)
compared with the same infected cells expressing a control
(scrambled sequence) shRNA (Figure 7B) or untransduced cells
Figure 2. Expression of NKG2D ligands on CD4pos T-cells following infection with viruses unable to express Vpr, Vif, Vpu or Nef.
Infected primary T-cell blasts [(A) Wild-type, (B) DVpr, (C) DVif, (D) DVpu and (E) DNef] and uninfected CD4pos T-cells were surface stained with
fluorochrome-conjugated anti-CD4 Ab and a fusion protein of human NKG2D and the Fc portion of human IgG1 along with fluorochrome-
conjugated goat anti-human IgG1. All cells were stained intracellularly for HIV-1 p24 Ag. Histograms were derived following acquisition on a flow
cytometer of either 104 viable CD4pos cells [(for uninfected cells) blue line] or 104 viable CD4neg and HIV-1 p24 Agpos infected cells (red line). The figure
is representative data from three separate experiments.
doi:10.1371/journal.ppat.1000613.g002
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(Figure 7A). Thus, NKG2D ligand expression on HIV-1-infected
cells is dependent on the Cul4aDCAF-1 ubiquitin ligase complex.
Manipulation of the Cul4aDCAF-1 complex by Vpr results in
ATR activation and G2 arrest [37]. It is formally possible that up-
regulation of ULBP-1 and -2 is also a consequence of
manipulation of Cul4aDCAF-1, but independent of ATR activation.
Alternatively, ATR activation may be required for ULBP up-
regulation, as was suggested by Gasser et al [29]. To differentiate
between these two possibilities, we treated DHIV-infected cells
with caffeine, a known inhibitor of ATR and its related kinase,
ATM [30,35,43]. As shown in Figure S5, caffeine, at a
concentration of 4 mM, eliminated the ability of HIV-1 to induce
G2 arrest from a ratio of G2+M/G1= 7.67 to ratio of G2+M/
G1= 0.53. Caffeine (4 mM) treatment of HIV-1-infected cells
dampened NKG2D ligand expression (Figure 8; MFI= 277 for
caffeine-treated virus-infected cells compared to MFI= 763 for
vehicle-treated virus-infected cells). Caffeine had little effect on
NKG2D ligand expression on uninfected cells (Figure 8;
MFI = 148 for caffeine-treated uninfected cells compared to
MFI= 103 for vehicle-treated uninfected cells). Thus, caffeine
inhibition of ULBP up-regulation suggests that ATR is a required
upstream mediator of NKG2D ligand expression.
Since caffeine inhibits both ATR and ATM [43] it is formally
possible that the effect of HIV Vpr on ULBP up-regulation is
dependent on both ATR and ATM. Thus, to determine any role
that ATM may play in the induction of NKG2D ligands by HIV,
we evaluated the effect of KU55933, an ATM-specific inhibitor on
NKG2D ligand expression [44]. Figure 9 shows that treatment of
infected cells with 10 mM KU55933 had little effect on NKG2D
ligand expression (MFI= 953) relative to infected cells treated with
vehicle alone (MFI= 955). In contrast, KU55933 did affect the
level of NKG2D ligands expressed on primary CD4pos T-cells
following treatment with aphidicolin, a DNA polymerase a
inhibitor which induces replication stress (MFI= 432) relative to
vehicle-treated cells (MFI= 792) (Figure S6). Unlike KU55933,
caffeine prevented NKG2D ligand expression on both HIV-1-
infected and aphidicolin treated cells (see Figures 9 and S6). Thus,
Vpr induces NKG2D ligand through activation of ATR but not
ATM.
Up-regulation of ULBP 1 and 2 by Vpr contributes to
killing by NK cells
Our studies, thus far, demonstrate that HIV-1 induces the
expression of ULBP-1 and ULBP-2 through Vpr. However,
whether Vpr mediated-induction of ULBP-1 and ULBP-2 on
infected cells constitutes a signal that will trigger NK cell lysis
remains to be determined. To address this, we compared the
ability of primary NK cells to lyse autologous T-cell blasts when
infected with either WT or DVpr viruses. As a control, we blocked
NKG2D on NK cells prior to exposure to target cells. If NKG2D
interaction with its ligands on infected cells had any role in
triggering NK cell lysis, then blocking NKG2D would abate the
effect. As shown in Figure 10, cells infected with WT virus are
sensitive to NK cell lysis, when compared with uninfected cells.
Infection with DHIV-DVpr led to a reduced level of NK-mediated
lysis (Figures 10 and S7). Although the reduction was not
complete, it is noteworthy that deletion of Vpr had a similar
effect as the blockade of NKG2D (Figure 10A). These observa-
tions, taken together, indicate that up-regulation of NKG2D
ligands by Vpr is responsible for a fraction of the observed lytic
activity by NK cells. Thus, we conclude that through its known
abilities to interact with the Cullin 4a-based E3 ubiquitin ligase
and activate ATR, Vpr induces expression of ULBP-1 and -2 and
this, in turn, constitutes a signal that triggers NK cell lysis of
infected cells.
Discussion
Our previous studies demonstrated that primary T-cell blasts
infected both in vitro and in vivo with HIV expressed, on their cell
surface, ligands for NKG2D [24,25]. Here, we demonstrate that
HIV-1 Vpr selectively induces expression of ULBP-1 and ULBP-2
gene products (Figures 4 and 5). ULBP-3, MIC-A and MIC-B
were hardly, if at all, up-regulated. We did not observe ULBP-4 on
HIV-infected cells using a recently generated anti-ULBP-4
monoclonal antibody (a gift from Dr. John Trowsdale, University
of Cambridge, Cambridge, England) in a separate experiment
(data not shown).
DNA damage leads to the expression of NKG2D ligands [29];
our observations here indicate that Vpr, through activation of the
DNA damage pathway, induces similar effects as those reported by
Gasser [29]. This ultimately leads to expression of ULBP-1 and -2
on the cell surface. Despite the potential abilities of both ATM and
ATR, following DNA damage, to induce NKG2D ligands [29],
only ATR in HIV-1 infected cells appears to trigger the expression
of NKG2D ligands. This is consistent with the previously reported
specificity of Vpr for ATR and not for ATM [30,31]. We now
show that Vpr enhances NKG2D ligand expression on infected
Figure 3. Vpr alone is capable of inducing NKG2D ligands
surface expression. Primary CD4pos T-cell blasts were transduced
with a lentivirus vector (pPR-Vip) coexpressing Vpr and GFP (red line).
As a control the same cells were infected with a lentivirus vector
expressing GFP only (green line). Following transduction cells were
stained with a fusion protein of human NKG2D and the Fc portion of
human IgG1 along with fluorochrome-conjugated goat anti-human
IgG1. Histograms were derived following acquisition on a flow
cytometer of either 104 viable cells [(for untransduced cells) blue line]
or 104 viable GFPpos cells (green and red line). The figure is
representative data from two separate experiments.
doi:10.1371/journal.ppat.1000613.g003
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cells and that ATR is required for this novel activity of Vpr (see
Figures 8 and 9).
The available literature on whether retroviruses activate DNA
damage responses upon integration remains controversial. Several
publications propose that HIV (and other retroviruses) do not
cause DNA damage signaling when they integrate [45,46] while
others have shown the participation and/or requirement of
checkpoint proteins and DNA damage sensors [47,48]. HIV-1
Vpr activates the DNA damage sensor, ATR, but importantly,
Vpr does not do so upon integration, but only after de novo
expression in the infected cells, well beyond the integration step
[46]. Furthermore, we found no evidence that the presence of Vpr
in virions early in infection enhanced the efficiency of viral
integration to any degree [46]. Accordingly, Vpr has been shown
to exert identical effects on the cell cycle when expressed via
systems devoid of viral integration (such as adenoviral vectors,
plasmid transfection, and tetracycline-inducible Vpr cell lines
[49,50,51]).
Recent studies from other investigators indicate that soluble Vpr
has an impact on NK cell activity [52]. Although we did not
directly assess the role of soluble Vpr, our observations produced
no evidence that soluble Vpr released by HIV-infected cells would
induce NKG2D ligands on uninfected cells. We base this notion
on the fact that uninfected (HIV-1 p24neg) cells within infected
cultures do not express NKG2D ligands on their surface. Only
HIV-1 p24pos cells express NKG2D ligands (see Figures 1 and S2).
Hence, we propose that Vpr must be expressed within the infected
cells in order to induce NKG2D ligand expression.
HIV-1 accessory gene products other than Vpr appear to have
no effect on the expression of NKG2D ligands. Our observations
here are in contrast to those of Cerboni et al. who showed that
HIV-1 Nef down-regulates ULBPs from the cell surface of Jurkat
Figure 4. Vpr is more likely to induce surface expression of ULBP-1 and ULBP-2 than ULBP-3, MIC-A or MIC-B on infected cells.
Primary CD4pos T-cell blasts were infected with wild-type (WT) HIV-1. As a control, the same cells were infected with HIV-1 that was deficient in
expression of Vpr (DVpr). As an additional control we evaluated uninfected CD4pos T-cells for expression of individual NKG2D ligands (blue lines).
Following infection, cells were surface stained using fluorochrome-conjugated mAb specific for: CD4 (A-J), ULBP-1 (A–B), ULBP-2 (C–D), ULBP-3 (E–F),
MIC-A (G–H) or MIC-B (I–J). The cells were then intracellularly stained for HIV-1 p24 antigen. Histograms were derived following acquisition of 104
viable uninfected CD4pos cells (blue line) or 104 viable CD4neg and HIV-1 p24 Agpos infected cells (red line). Green line represents the histogram of
staining controls (isotype controls). The figure is representative data from two separate experiments.
doi:10.1371/journal.ppat.1000613.g004
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T-cells [26]. The contradictory observations made in our studies
may suggest that there are differences in the ability of Nef to
modulate NKG2D ligands between activated primary T-cells and
transformed T-cell lines. The DNef virus we used in our study does
not express Nef even though it expresses Vpr (Figure S8B).
The Cul4aDCAF-1 ubiquitin ligase contributes to the ability of
Vpr to arrest HIV-1-infected cells in G2 phase of the cell cycle
[38,39]; in our current studies we showed that this ligase is
important in Vpr-induced NKG2D ligand expression as well. E3
ubiquitin ligases transfer ubiquitin molecules to specific substrates.
Poly-ubiquitination can mark substrates for degradation by the
proteasome. We attempted to test the role of proteasomal
degradation in induction of NKG2D ligands. Unfortunately,
proteasome inhibitors were highly toxic to primary T-cells and,
therefore, the possible role of proteasomal activity in degrading
NKG2D ligands is unknown at this time (data not shown).
Our expectation was that induction of cell-surface expression of
ULBP-1 and ULBP-2, would trigger NK cells to kill infected cells.
This indeed is what we found, since NK cells have a decreased
ability to lyse virus-infected cells lacking Vpr. Moreover, the
reduction in killing activity of the DVpr virus was strikingly similar
to that obtained against WT virus-infected cells in which we
masked the NKG2D receptor. We have reported, in previous
published studies, that variations exist between HIV-infected
donors in the capacity of their NK cells to kill autologous HIV-
infected cells [25]. We observed killing from as little as 4% and as
high as 20% in 8 donors using an E:T ratio of 10:1 [25].
Importantly, The level to which NK cells lysed HIV-infected
targets directly correlated with the extent to which ULBP2 was
expressed on the surface of the infected cells [25]. Those
observations provide indirect support to our model that Vpr,
through enhancing ULBP expression, may prime cells for lysis by
NK.
NK cell function in HIV-infected individuals is similar to that of
uninfected individuals unless the patient is highly viremic [53].
These viremic patients typically possess a dysfunctional NK cell
subpopulation lacking CD56 but retaining CD16 [54]. Despite the
presence of dysfunctional NK cells in viremic individuals, there are
subpopulations of functional NK cells in these patients [53] with
residual ability to lyse autologous HIV-infected cells [25]. It has
been shown that this residual activity required recognition of
NKG2D ligands on the infected cell surface [25].
Based on our studies, the expected consequence of Vpr’s
induction of ULBP-1 and -2 would be that HIV-1-infected cells
would become sensitive to killing by NK cells. This scenario would
clearly be detrimental to virus replication. A logical explanation
Figure 5. Vpr is involved in upregulating the expression of ULBP-1 and ULBP-2 mRNA. RNA was extracted from HIV-infected CD4pos T-cell
blasts and uninfected cells and reverse transcribed. Relative copy numbers of NKG2D ligands were determined by real-time PCR using NKG2D-ligand
specific primer pairs and normalized relative to GAPDH expression. The relative increase in copy numbers was calculated as described in Materials
and Methods. The relative copy numbers for the indicated primer pair in uninfected cells was set to 1. Error bars indicate the standard deviations of
the mean of samples in triplicate.
doi:10.1371/journal.ppat.1000613.g005
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for this paradox is that up-regulation of ULBPs by Vpr is a
downstream consequence of its biological activity (e.g., Vpr
induces LTR transactivation in the G2 phase of the cell cycle
[32]). Therefore, we hypothesize that other unknown cellular
factors may compensate for the activity of Vpr to collectively
modulate the sensitivity of HIV-infected cells to lysis by NK cells.
Figure 6. Regions of Vpr that are involved in the ability of Vpr to induce arrest in the cell cycle at the G2 phase are also important in
NKG2D ligand expression. Primary T-cell blasts infected with wild type HIV-1 and HIV-1 with various mutations in Vpr were surface stained with
fluorochrome-conjugated anti-CD4 Ab and a fusion protein of human NKG2D and the Fc portion of human IgG1 along with fluorochrome-
conjugated goat anti-human IgG1. Uninfected CD4pos T-cells were surface stained in a similar fashion. All cells were stained intracellularly for HIV-1
p24 Ag. The mean fluorescent intensity of NKG2D ligand staining was obtained from collection of 104 CD4neg p24pos cells for all infected cells, and of
the 104 CD4pos p24neg cells for the uninfected control. This figure is a representative of three separate experiments.
doi:10.1371/journal.ppat.1000613.g006
Figure 7. The DCAF1 subunit of Cul4a E3 ubiquitin ligase is involved in the ability of HIV-1 to induce surface expression of NKG2D
ligands. Primary CD4pos T-cell blasts were transduced with shRNA of a DCAF1-specific sequence (C) or an shRNA with a scrambled sequence (B).
Untransduced cells were used as a negative control (A). The cells were then infected and stained with anti-CD4 Ab and a fusion protein of human
NKG2D and the Fc portion of human IgG1 along with fluorochrome-conjugated goat anti-human IgG1. Transduced cells were detected by GFP
expression. The figure is representative data from two separate experiments.
doi:10.1371/journal.ppat.1000613.g007
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It is difficult to reconcile how HIV-1 could persist if it increases
the likelihood of being destroyed by NK cells through induction of
ULBP-1 and ULBP-2 (Figure 4) by Vpr on the cell surface and
down modulating ligands (i.e., HLA-A and –B) to NK cell
inhibitory receptors by Nef [55]. Part of the answer may lie in the
fact that Nef does not down modulate HLA-C and HLA–E
Figure 8. Inhibition of ATR activity relieves Vpr-induced NKG2D-ligand expression. Primary CD4pos T-cells were infected in the presence
(C) or absence (B) of the ATR inhibitor, caffeine. As controls CD4pos T-cells were not infected (A) but treated with caffeine or vehicle. Following
exposure to 4 mM caffeine and HIV-1 infection, NKG2D ligand expression on the surface of infected cells was measured by staining with a fusion
protein of human NKG2D and the Fc portion of human IgG1 along with fluorochrome-conjugated goat anti-human IgG1. The histograms are gated
for either 104 viable CD4pos/HIV-1 p24neg cells (blue) or on 104 viable CD4neg HIV-1 p24pos cells (red). This figure is representative of three separate
experiments.
doi:10.1371/journal.ppat.1000613.g008
Figure 9. Inhibition of ATM does not affect NKG2D-ligand expression on infected cells. Primary CD4pos T-cells were infected in the
presence (B) of the ATM-specific inhibitor KU55933 (10 mM). As a positive control infected cells were treated with 4 mM caffeine (C). Negative controls
included vehicle-treated infected cells (A) or CD4pos T-cells infected with HIV-1 lacking Vpr [(DVpr) D]. Following exposure to inhibitors and HIV-1
infection, NKG2D ligand expression on the surface of infected cells was measured by staining with a fusion protein of human NKG2D and the Fc
portion of human IgG1 along with fluorochrome-conjugated goat anti-human IgG1. The histograms are gated for either 104 viable CD4pos/HIV-1
p24neg cells (blue) or on 104 viable CD4neg HIV-1 p24pos cells (red). MFI =mean fluorescent intensity. This figure is representative of three separate
experiments.
doi:10.1371/journal.ppat.1000613.g009
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Figure 10. Vpr is involved in triggering NK cells to kill the infected cell. Primary CD4pos T-cell blasts were infected with HIV-1 that was
deficient in expression of Vpr (DVpr) (A&B). As a control, the same cells were infected with wild-type (WT) HIV-1 (A&B). Following infection the
infected cells were isolated, labeled with 51Cr and mixed with autologous NK cells at 2.5:1 (open bars) and 5:1 (closed) effector cell to target cell ratios.
Each group was done in triplicate. Prior to the lytic assay some of the NK cells were exposed to blocking antibodies to NKG2D (A). At the end of the
incubation period culture fluids were harvested and analyzed for the presence of 51Cr. Percent specific lysis was determined as described in the
Materials and Methods section. Error bars represent standard deviation of the mean. The figure is representative of two separate experiments.
*p,0.05, **p,0.01 by the Student’s t-test.
doi:10.1371/journal.ppat.1000613.g010
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[55,56]. We have published previously [56] that NK cells lacking
HLA-C and –E inhibitory receptors kill infected cells by 5-20-fold
over unsorted NK cells. Blocking HLA-C and –E on HIV-infected
cells from interacting with inhibitory receptors on NK cells
enhances NK cells’ ability to kill HIV-infected cells [56]. Overall
these findings indicate that HLA-C and –E on the infected cells
prevent NK cells from killing the infected cells because inhibitory
receptors are engaged on NK cells. However, our previous study
also indicated that a sufficient number of NK cells lack HLA-C
and HLA–E inhibitory receptors and thus would not be inhibited
by these MHC class I molecules [55,56].
The presence of ULBP-1, ULBP-2 on the infected cell surface
would allow the subpopulation of NK cells not regulated by HLA-C
and HLA–E to kill the HIV-1-infected cells. However, NK cells are
also regulated at the level of coactivating receptors [57].
Degranulation by NK cells following the triggering of NKG2D
requires simultaneous engagement of co-activating receptors such as
2B4 or NTB-A by their ligands on target cells [57]. Therefore, the
relatively low lytic activity induced by Vpr through ULBP-1 and -2
induction could be explained on the basis of lack of concomitant
induction of coactivating ligands. Recently we demonstrated that
co-activating ligands are important for NK cell destruction of HIV-
1-infected cells [24] and that HIV-1 down modulates the
coactivating receptor ligands [24,25]. This would then make the
infected cell less vulnerable to destruction since activated NK cells
will have a reduced ability to degranulate. We are currently
investigating how HIV-1 down modulates the ligands for the NK
cell coactivating receptors in order to test this hypothesis.
Our observation that HIV-1 Vpr induces NK cell ligands opens
a new set of questions that will need to be addressed in the near
future. Specifically, it will be compelling to ascertain whether up-
regulation of ULBP-1 and 2 by Vpr can be exploited
therapeutically, such that HIV-1 infected cells can be manipulated
to become more susceptible to NK lysis; (ii) whether other
accessory or, in general, viral proteins can manipulate other
aspects of the NK response; and (iii) the signaling steps linking
activation of cell cycle checkpoint proteins and the increase in
steady-state mRNA levels for NKG2D ligands.
Materials and Methods
Antibodies and fusion proteins
The mouse anti-human CD4, CD16, CD56, CD112 and MIC-
A/MIC-B monoclonal antibodies (mAbs) were obtained from BD
Biosciences (http://www. bdbiosciences.com/). The soluble fusion
protein of the NKG2D receptor with the Fc portion of human IgG
and mouse anti-human NKG2D, ULBP-1, ULBP-2, and -3
antibodies (Abs) were obtained from R&D Systems (www.
rndsystems.com). The anti-MIC-A and MIC-B mAbs that do
not cross-react with one another were obtained from Axxora
(www.axxora.com). The fluorochrome-conjugated goat anti-hu-
man IgG1 Fc-specific secondary Ab (with minimal cross-species
reaction) was obtained from Jackson ImmunoResearch Laborato-
ries (www.jacksonimmuno.com) and the fluorochrome-conjugated
rabbit anti-mouse IgG secondary Ab was from Dako (www.dako.
com). The mouse anti-HIV-1 p24 mAb, KC57, was obtained from
Beckman Coulter (Fullerton, CA) and the mouse monoclonal
Ab clone AG3.0 was obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program (www.
aidsreagent.org) and was deposited by Dr J. Allan [58].
Cells and culture reagents
All primary cells used in this study were isolated from peripheral
blood drawn from all healthy donors after informed written
consent was obtained in accordance with the Declaration of
Helsinki and the policies of the Institutional Review Board at Rush
University Medical Center, Chicago, IL. Peripheral blood
mononuclear cells (PBMC) were isolated by centrifugation
(10006 g, 20 min 20uC of peripheral blood over a Ficoll-hypaque
gradient (Mediatech, http://www.cellgro.com/). CD4pos T-cells
were isolated from PBMC by negative selection using a CD4pos T-
cell isolation kit (Dynal, http://www.invitrogen.com/) and
stimulated with anti-CD3/anti-CD28 mAb-coated microbeads
(Dynal) in RPMI complete medium that consisted of RPMI
medium (Mediatech) supplemented with 10% heat inactivated
(56uC, 30 min) fetal bovine serum (FBS) (Mediatech) and
penicillin/streptomycin (Mediatech) before infection with DHIV
or transduction with lentivirus vectors. The Jurkat E6-1 cell line
was obtained from the American Type Culture Collection (http://
www.atcc.org/) and was maintained in RPMI complete medium.
The 293 FT cell line (Invitrogen), used in the generation of virus
and vectors, was maintained according to the manufacturer’s
specifications. Caffeine was obtained from the Sigma Chemical
Company (http://www.sigma.com/). KU55933 was obtained
from Calbiochem (http://www.calbiochem.com). Aphidicolin
was obtained from the Sigma Chemical Company. KU55933
and aphidicolin stock solutions were prepared by dissolving the
drugs in DMSO (Sigma Chemical Company) at 1 mM concen-
tration prior to their addition to medium at a final concentration
of 10 mM.
Virus vectors
The envelope-defective DHIV vector is isogenic to the HIV
molecular clone HIV-1NL4/3. To construct DHIV vectors with
premature stop-codons in the nef, vpu, vif and vpr open reading
frames or containing mutated vpr genes, base changes were made
by site-directed mutagenesis (Quikchange II XL, www.stratagene.
com) of subcloned fragments and cloning the mutagenized
fragments back into DHIV. All mutations were sequenced to
verify accurate mutagenesis, and Western blotting of lysates from
DHIV-infected CD4pos Jurkat E6-1 cells was used to verify correct
protein expression (Figure S8). DHIV-DVpu was verified to lack
Vpu activity by its inability to down modulate CD4 molecules on
primary T-cells (data not shown).
The FG12 vector system was graciously provided by Dr. Dong
Sung An (University of California, Los Angles, CA). The
DCAF1_3590 target sequences have been reported previously
[42]. The scrambled sequence was 59 GCATATCCACCGT-
GAGTGT 39. All target sequences were obtained as olignucleo-
tides (IDT, www.idtdna.com), annealed, and inserted downstream
of the H1 RNA polymerase III promotor as described [59].
Western blots of lysates of primary activated T-cells transduced
with the DCAF_3590 sequence produce less DCAF1 (Figure S9).
pPR-Vip, the lentivirus vector that expressed HIV-1 Vpr and
GFP, was generated as described previously [30].
Vesicular stomatitis virus (VSV)-G protein pseudotyped FG12,
pPR-VIP and DHIV vectors were produced as previously
described [36]. Viral vectors were titered by spin-inoculation at
12006 g for two hr at 20uC of dilutions of viral supernatant onto
the Jurkat E6-1 cell line and detection of either intracellular HIV-1
p24 antigen (DHIV) or GFP expressing cells (FG12) by flow
cytometry and the calculation of titers as described [36].
Infections/transduction
Primary T-cells were activated using anti-CD3/anti-CD28
mAb coupled to magnetic beads for 48 hr for DHIV and pPR-
VIP or 24 hr for the FG12 vector. Infection/transduction was
done by spin-inoculated as described [60] at an MOI of five for
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DHIV, ten for the FG12 vector, and five for pPR-VIP. For HIV-
1NL4/3 infection; an MOI of 0.01 was used. Following the
infection, the cells were cultured in RPMI complete medium with
100 U/mL recombinant IL-2 (AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, deposited by
Dr. Maurice Gately, Hoffmann-La Roche Inc, Nutley, NJ; [61]).
For experiments where cells were transduced with the FG12
vector and then infected with DHIV, CD4pos T-cells were
activated with anti-CD3/anti-CD28 mAb-coated microbeads,
transduced with the FG12 vector, cultured for an additional
48 hr, and then infected with DHIV.
Flow cytometry
Simultaneous detection of surface antigens and intracellular
HIV-1 p24 antigen (Ag) was done as previously described [24].
Infected cells were designated by the absence of CD4 and the
presence of HIV-1 p24 Ag (Figure S1). For analysis of cell cycle
profiles, cells were stained for the appropriate surface markers,
washed with FACS buffer (PBS containing 0.1% NaN3 and 2%
FBS) fixed for 20 min on ice with 0.25% paraformaldehyde,
and permeabilized for 20 min on ice with 0.1% Triton X-100
in PBS. Following a wash in FACS buffer, intracellular staining
was performed for HIV-1 p24 Ag and washed a final time.
DNA was stained using 1 mM TO-PRO-3 (Invitrogen) in
FACS buffer supplemented with 11.25 Kunitz units/mL
RNAse (Sigma) and promptly analyzed on an LSR II flow
cytometer (BD).
Purification of infected cells for cytotoxicity assays and
real-time RT-PCR
Forty-eight hrs after infection culture, CD4neg p24pos cells were
purified by removing CD4pos p24neg cells with anti-CD4 mAb coated
magnetic beads (Dynal). To eliminate dead cells the Dead Cell
removal kit from Miltenyi was used (http://www.miltenyibiotech.
com/). Purity of infected cells was routinely greater than 95% as
determined by flow cytometry.
Real-time RT-PCR
Primer pairs for detection of ULBP-1, ULBP-2, ULBP-3, MIC-
A and MIC-B were obtained from previous studies described in
[62]. The primer pair used for GAPDH was 59 GCACCGT-
CAAGGCTGAGAAC 39 (sense) and 59 GGATCTCGCTCC-
TGGAAGATG 39 (antisense). Total RNA was isolated using the
RNAqueous Kit (Ambion, www.ambion.com) and treated with
DNAse (TURBO DNA-Free, Ambion). Reverse-transcription and
real-time RT-PCR reactions were carried out using the Super-
script III Platinum Two-Step qRT-PCR kit using Sybr Green
chemistry (Invitrogen) according to the manufacturer’s protocol.
The cDNA was amplified in triplicate with the ABI 7500 Real-
Time PCR System (Applied Biosystems, www.appliedbiosystems.
com) with indicated primer pairs for 40 cycles at 95uC for 15 sec
and 60uC for one min. Analysis was done by using the DCT
method for relative quantification as previously described [62]
except that GAPDH was used as a reference. Similar amplification
efficiencies for NKG2D ligand and GAPDH were demonstrated
by analyzing serial cDNA dilutions with values of the slope of log
cDNA amount vs. DCT of ,0.1. Threshold cycles (CT) for
GAPDH (reference) and NKG2D ligands (sample) were deter-
mined in triplicate. We defined the values obtained for uninfected
cells as standard values and determined the relative increase (rI) in
copy numbers in relation to these standard values according to the
formula: rI = 2ˆ2[(CT Sample2CT Reference)2(CT StandardSample2CT Standard Reference)].
Cytotoxicity assay
The cytotoxicity of HIV infected cells by autologous NK was
measured using the 51Cr release assay. The cytotoxicity assay was
done according to the methods previously described in [24].
Supporting Information
Figure S1 Gating strategy used for detection of NKG2D ligands
on infected cells. Infected primary T-cell blasts and uninfected
CD4pos T-cells were surface stained with anti-CD4 Ab. All cells
were stained intracellularly for HIV-1 p24 antigen (Ag). Cells were
then incubated in the presence of Aquadead stain kit (Invitrogen)
to distinguish viable and non-viable cells. Throughout the study
NKG2D ligands were evaluated on either 104 viable uninfected
(CD4pos HIV-1 p24 Agneg cells) or 104 viable infected cells
(CD4neg HIV-1 p24 Agpos). FSC= forward scatter, SSC= side
scatter. Gates in red indicate selection process for infected and
uninfected cells.
Found at: doi:10.1371/journal.ppat.1000613.s001 (2.48 MB TIF)
Figure S2 NKG2D ligands are not expressed on CD4pos T-cells
infected with DVpr HIV-1. Infected primary T-cell blasts and
uninfected CD4pos T-cells were surface stained with a fusion
protein of human NKG2D and the Fc portion of human IgG1
along with fluorochrome-conjugated goat anti-human IgG1. All
cells were stained intracellularly for HIV-1 p24 antigen (Ag). Two-
dimensional plots were derived following acquisition on a flow
cytometer of 104 viable cells. Markers in dot plots were positioned
based on the staining controls. The figure is representative data
from three separate experiments.
Found at: doi:10.1371/journal.ppat.1000613.s002 (0.98 MB TIF)
Figure S3 Effect of point mutations in postions 65 and 80 of Vpr
on the cell cylcle of HIV-infected cells. Infected primary T-cell
blasts and uninfected CD4pos T-cells were stained with TO-PRO-
3 in order to obtain the (G2+M)/G1 ratio.
Found at: doi:10.1371/journal.ppat.1000613.s003 (0.67 MB TIF)
Figure S4 Expression of DCAF1 is not affected by HIV-1 Vpr.
The HeLa cell line was either treated with 10 mM aphidocolin
(Aph), or infected with VSV-G pseudotyped HIV-1 with wild-type
Vpr (Vpr) or HIV with Q65R and R80A mutations in Vpr (Vpr
QR). Following treatment/infection cells lysates were made and
western blotted. Western blots were probed with DCAF1 specific
antibody.
Found at: doi:10.1371/journal.ppat.1000613.s004 (0.56 MB TIF)
Figure S5 Inhibition of ATR activity relieves Vpr-induced G2
arrest. Primary CD4pos T-cell blasts were exposed to 4 mM of the
ATR inhibitor, caffeine (B and D) or vehicle (A or C) and either
infected with HIV-1 (C and D) or left uninfected (A and B). Forty-
eight hrs. following exposure to caffeine and HIV-1 infection the
cell cycle profile of the uninfected and infected cells were detected
by TO-PRO-3 staining.
Found at: doi:10.1371/journal.ppat.1000613.s005 (1.50 MB TIF)
Figure S6 Inhibition of ATM activity reduces NKG2D ligand
expression on primary CD4pos T-cells treated with aphidocolin.
Primary CD4pos T-cells were treated with 10 mM aphidicolin in
the presence of 10 mM KU55933 (ATM-specific inhibitor) or
4 mM caffeine. As a negative control aphidicolin-treated cells were
exposed to vehicles used to dissolve the inhibitor in solution.
Following 48 h exposure to KU55933, caffeine or vehicle the cells
were stained with a fusion protein of human NKG2D and the Fc
portion of human IgG1 and fluorochrome conjugated-goat anti-
human IgG Fc specific antibody (blue line) or secondary antibody
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alone [staining control (red line)]. The histograms are gated for 104
viable CD4pos cells. This is a representative of two experiments.
Found at: doi:10.1371/journal.ppat.1000613.s006 (0.71 MB TIF)
Figure S7 Ability of NK cells to lyse autologous T-cells infected
with HIV-1 lacking Vpr. Primary CD4pos T-cell blasts were
infected with HIV-1 that were deficient in expression of Vpr
(DVpr). As a control, the same cells were infected with wild-type
(WT) HIV-1. Following infection the infected cells were isolated,
labeled with 51Cr and mixed with autologous NK cells at 2.5:1 (A
and C) and 5:1 (B and D) effector cell to target cell ratios. Prior to
the lytic assay some of the NK cells were exposed to blocking
antibodies to NKG2D (C and D). At the end of the incubation
period culture fluids were harvested and analyzed for the presence
of 51Cr. Percent specific lysis was determined as described in the
Materials and Methods section. Each point designates a sample
from each group. Bars represent the mean percent specific lysis.
This supplemental figure is a dot plot representation of Figure 10.
Found at: doi:10.1371/journal.ppat.1000613.s007 (1.02 MB TIF)
Figure S8 Expression of viral proteins by various HIV-1
mutants. HIV-1-infected CD4pos cells were lysed in cell lysis
buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4,
0.25% Na-deoxycholate, 1 mM EDTA. 1 mM PMSF, 1 mM
Na3VO4, 0.1% SDS, and protease inhibitors), run on 15% SDS-
PAGE gels, transferred to PVDF, and probed for the indicated
proteins with specific antibodies. (A) Lysates from CD4pos cells
infected with DHIVDVpr, DHIVDVif, DHIVDVpr,DVif or
DHIV containing Vpr with point mutations in specific residues.
(B) Lyates from CD4pos T-cells infected with DHIVDNef.
Found at: doi:10.1371/journal.ppat.1000613.s008 (3.19 MB TIF)
Figure S9 Ability of shRNA expressing either scrambled or
DCAF1 specific sequence to down modulate DCAF1 in
transduced cells. Primary T-cell blasts were transduced with the
shRNA with specific sequences, sorted by FACS to greater than
95% purity based on GFP expression, lysed in cell lysis buffer (1%
NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 0.25% Na-
deoxycholate, 1 mM EDTA. 1 mM PMSF, 1 mM Na3VO4, 0.1%
SDS, and protease inhibitors), run on 15% SDS-PAGE gels,
transferred to PVDF, and probed for the either DCAF1 or b-actin
proteins with specific antibodies.
Found at: doi:10.1371/journal.ppat.1000613.s009 (1.57 MB TIF)
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